Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One-Year Follow-Up Results From the Observational, Multicenter, Prospective, and Controlled Registry: The WALTZ All-Comers Study.
Rodriguez AE, Larribau M, Fernandez-Pereira C, Iravedra J, Santaera O, Haiek C, Lloberas J, Montoya M, Sisu E, Menendez M, Pavlovsky H, Rodriguez-Granillo AM, Mieres J, Romero G, Ming Z, Pan W, Antoniucci D. Rodriguez AE, et al. Among authors: mieres j. Clin Med Insights Cardiol. 2019 Jun 27;13:1179546819854059. doi: 10.1177/1179546819854059. eCollection 2019. Clin Med Insights Cardiol. 2019. PMID: 31285655 Free PMC article.
Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry.
Rodriguez AE, Maree AO, Mieres J, Berrocal D, Grinfeld L, Fernandez-Pereira C, Curotto V, Rodriguez-Granillo A, O'Neill W, Palacios IF. Rodriguez AE, et al. Among authors: mieres j. Eur Heart J. 2007 Sep;28(17):2118-25. doi: 10.1093/eurheartj/ehm297. Epub 2007 Jul 25. Eur Heart J. 2007. PMID: 17656352
Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study.
Rodriguez AE, Maree A, Tarragona S, Fernandez-Pereira C, Santaera O, Rodriguez Granillo AM, Rodriguez-Granillo GA, Russo-Felssen M, Kukreja N, Antoniucci D, Palacios IF, Serruys PW; ORAR III Investigators. Rodriguez AE, et al. EuroIntervention. 2009 Jun;5(2):255-64. doi: 10.4244/eijv5i2a40. EuroIntervention. 2009. PMID: 20449934 Clinical Trial.
Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
Rodriguez AE, Vigo CF, Delacasa A, Mieres J, Fernandez-Pereira C, Bernardi V, Bettinoti M, Rodriguez-Granillo AM, Rodriguez-Granillo G, Santaera O, Curotto V, Rubilar B, Tronge J, Palacios IF, Antoniucci D; EUCATAX Investigators. Rodriguez AE, et al. Among authors: mieres j. Catheter Cardiovasc Interv. 2011 Feb 15;77(3):335-42. doi: 10.1002/ccd.22769. Epub 2010 Nov 30. Catheter Cardiovasc Interv. 2011. PMID: 20824769 Clinical Trial.
Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, Mieres J, Fernandez-Pereira C, Rodriguez-Granillo GA, Santaera O, Rubilar B, Palacios IF, Serruys PW; ORAR III Investigators. Rodriguez AE, et al. Among authors: mieres j. Catheter Cardiovasc Interv. 2012 Sep 1;80(3):385-94. doi: 10.1002/ccd.23352. Epub 2011 Dec 8. Catheter Cardiovasc Interv. 2012. PMID: 22109997 Clinical Trial.
132 results